Current Rheumatology Reports最新文献_第5页

Treatment of Persons with Rheumatoid Arthritis with a History of Cancer. 有癌症病史的类风湿关节炎患者的治疗。

IF 4.9 2区医学

Current Rheumatology Reports Pub Date : 2025-08-11 DOI: 10.1007/s11926-025-01200-0

Beeta Shasti-Nazem, Sanyogita Chandra, Jennifer Strouse, Namrata Singh

{"title":"Treatment of Persons with Rheumatoid Arthritis with a History of Cancer.","authors":"Beeta Shasti-Nazem, Sanyogita Chandra, Jennifer Strouse, Namrata Singh","doi":"10.1007/s11926-025-01200-0","DOIUrl":"10.1007/s11926-025-01200-0","url":null,"abstract":"Purpose of review: This review article examines the evolving evidence on cancer recurrence and new malignancy risk associated with disease-modifying antirheumatic drugs (DMARDs), including TNF inhibitors, rituximab, IL-6 inhibitors, and JAK inhibitors, in patients with rheumatoid arthritis and a prior malignancy.Recent findings: Conventional synthetic DMARDs are generally considered safe in patients with a history of cancer, with earlier concerns about skin and hematologic malignancies largely disproven. Hydroxychloroquine, sulfasalazine, and leflunomide similarly show no consistent cancer risk. Biologic DMARDs, including TNF inhibitors, rituximab, and abatacept, have not been linked to increased cancer recurrence, though caution is advised in patients with a history of skin cancer. Despite supportive evidence, bDMARD use has declined following cancer diagnoses. JAK inhibitors, however, have shown increased risk of lung cancer in older patients with cardiovascular risk factors, prompting cautious use until more data is available. Although large population clinical trials are lacking, current evidence does not demonstrate any increased risk with initiation of csDMARDs, TNF inhibitors, and rituximab in RA patients with a history of cancer. Abatacept and IL-6 inhibitors may also be reasonable options but require further data. JAK inhibitors should be used cautiously until more reliable data becomes available. These findings support cautious but not prohibitive use of bDMARDs in RA patients with a history of cancer, emphasizing individualized risk assessment and shared decision-making. Further high-quality, prospective studies are needed to guide therapy in this complex clinical population.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"34"},"PeriodicalIF":4.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13217633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Family Planning and Rheumatoid Arthritis. 更正：计划生育与类风湿关节炎。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2025-07-31 DOI: 10.1007/s11926-025-01196-7

Catherine Sims, Mehret Birru Talabi

引用次数: 0

Quality Care Assessment in Gout. 痛风的质量护理评估。

IF 4.9 2区医学

Current Rheumatology Reports Pub Date : 2025-07-30 DOI: 10.1007/s11926-025-01199-4

Timothy S H Kwok, Priyanka Chandratre

{"title":"Quality Care Assessment in Gout.","authors":"Timothy S H Kwok, Priyanka Chandratre","doi":"10.1007/s11926-025-01199-4","DOIUrl":"10.1007/s11926-025-01199-4","url":null,"abstract":"Purpose of review: Despite the availability of effective pharmacotherapy to lower serum urate (SUA) levels and consequently reduce the likelihood of flares, gout remains a poorly managed condition. Quality of care assessments are of paramount importance in evaluating the performance of health systems and providers in managing gout, spanning patient (micro), provider or team (meso), and organizational or system-wide (macro) levels. This review focuses on the conceptual underpinnings on how quality of care in gout management is defined and assessed, highlighting methodological challenges, study approaches and contemporary findings.Recent findings: We illustrate the advantages and pitfalls on the use of quality indicators as the reference by which gout clinical care is deemed to be \"optimal\". We further introduce pertinent processes/intermediaries of gout care under a conceptual framework for quality assessment. Overall, quality of gout care requires significant improvement, with widespread deficiencies across key parameters including urate lowering therapy (ULT) adherence (micro-level), SUA monitoring (meso-level) and treatment to target SUA levels on a population basis (macro-level). There are large care gaps across processes, intermediaries and outcomes of gout care. Since accurate quality assessment forms the foundational pillar of subsequent quality improvement, this review serves as a reference to advance quality of gout care assessments. Further initiatives are required to enhance ULT adherence, in particular, which is a key intermediary step to optimal gout care and yet remains suboptimal on a population level. The integration of Learning Health Systems is emerging as a promising platform for improving the quality of gout care.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"32"},"PeriodicalIF":4.9,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Manifestations in Behçet's Syndrome. behaperet综合征的心脏表现。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2025-07-17 DOI: 10.1007/s11926-025-01190-z

Federica Bello, Giacomo Bagni, Emire Seyahi, Emanuele Chiara, Iacopo Olivotto, David Saadoun, Giacomo Emmi

{"title":"Cardiac Manifestations in Behçet's Syndrome.","authors":"Federica Bello, Giacomo Bagni, Emire Seyahi, Emanuele Chiara, Iacopo Olivotto, David Saadoun, Giacomo Emmi","doi":"10.1007/s11926-025-01190-z","DOIUrl":"10.1007/s11926-025-01190-z","url":null,"abstract":"Purpose of the review: Behçet's Syndrome (BS) is a multisystemic vasculitis that can affect the heart, leading to pericarditis, myocarditis, intracardiac thrombosis, endomyocardial fibrosis, valvular dysfunction, and coronary artery disease. This review summarizes the clinical presentation, diagnostic challenges, and therapeutic strategies for cardiac involvement in BS.Recent findings: Advanced imaging techniques have revealed subclinical cardiac involvement in BS. Myocardial dysfunction and fibrosis contribute to heart failure and arrhythmias, while intracardiac thrombi often coexist with pulmonary artery involvement. Coronary artery vasculitis and aneurysms may mimic atherosclerotic disease, complicating diagnosis. Biologic therapies, including TNF-α inhibitors, show promise in refractory cases. Early diagnosis and immunosuppressive therapy are crucial. A multidisciplinary approach is essential to managing cardiac complications and optimizing patient outcomes. Future research should refine screening protocols and explore targeted immunotherapies for BS-related cardiovascular disease.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"31"},"PeriodicalIF":3.9,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ectopic Nociceptor Sprouting as a Key Peripheral Driver of Pain in Rheumatoid Arthritis. 异位伤害感受器萌芽是类风湿关节炎疼痛的关键外周驱动因素。

IF 3.9 2区医学

Current Rheumatology Reports Pub Date : 2025-07-16 DOI: 10.1007/s11926-025-01198-5

Jayden A O'Brien, Joseph B Lesnak, Theodore J Price

{"title":"Ectopic Nociceptor Sprouting as a Key Peripheral Driver of Pain in Rheumatoid Arthritis.","authors":"Jayden A O'Brien, Joseph B Lesnak, Theodore J Price","doi":"10.1007/s11926-025-01198-5","DOIUrl":"10.1007/s11926-025-01198-5","url":null,"abstract":"Purpose of review: Pain is one of the most debilitating sequelae of rheumatoid arthritis. Established and emerging therapies offer effective disease control for many patients, though they often have underwhelming efficacy for pain relief. The uncoupling of pain intensity from disease activity and inflammation presents an ongoing challenge in both our understanding of the pathophysiology and our ability to treat joint pain. The generation of high-parameter, unbiased -omic data sets generated from patient-derived tissues is changing how we think about rheumatoid arthritis pain. In this review, we discuss the peripheral drivers of pain in rheumatoid arthritis-affected joints and their innervating primary afferents. We evaluate how human molecular immunology and neuroscience approaches are helping us unravel the heterogeneity of pain in rheumatoid arthritis and propose future directions to clarify how pain is maintained in the absence of inflammation.Recent findings: Synovial fibroblasts have emerged as key pronociceptive drivers within the rheumatic joint. Further to the classical proinflammatory mediators known to drive pain, such as cytokines and prostaglandins, bone morphogenetic proteins, ephrin signaling, and netrins appear to be upregulated in both rheumatoid arthritis-affected synovium and the innervating sensory neurons. Resulting adaptations to innervating primary afferents such as synaptogenesis and neurite outgrowth may occur in a sensory neuron subtype-specific manner causing pain that is disproportionate to inflammation. Nociceptor sprouting in the joint may explain why pain tends to persist despite adequate disease control. Future mechanistic work exploring the conditions under which these nociceptors sprout into the joint will provide new therapeutic avenues for ensuring that pain resolves alongside the inflammation associated with rheumatoid arthritis.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"30"},"PeriodicalIF":3.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spondyloarthritis Research and Treatment Network (SPARTAN) Clinical and Imaging Year in Review 2024. 脊柱关节炎研究和治疗网络（SPARTAN）临床和影像学回顾2024年。

IF 4.9 2区医学

Current Rheumatology Reports Pub Date : 2025-07-01 DOI: 10.1007/s11926-025-01195-8

Renato Ferrandiz-Espadin, Jean W Liew

{"title":"Spondyloarthritis Research and Treatment Network (SPARTAN) Clinical and Imaging Year in Review 2024.","authors":"Renato Ferrandiz-Espadin, Jean W Liew","doi":"10.1007/s11926-025-01195-8","DOIUrl":"10.1007/s11926-025-01195-8","url":null,"abstract":"Purpose of review: Diagnostic delay remains a critical challenge in axial spondyloarthritis (axSpA). This review highlights key clinical and imaging research from 2024 that addresses this persistent issue, with a focus on the evolving roles of MRI, artificial intelligence (AI), and updated Canadian management recommendations.Recent findings: Multiple studies published in 2024 emphasized the continued problem of diagnostic delay in axSpA. Studies support the continued use of sacroiliac joint MRI as a central diagnostic tool for axSpA, particularly in patients with chronic back pain and associated conditions like uveitis, psoriasis (PsO), or inflammatory bowel disease. AI-based tools for interpreting sacroiliac joint MRIs demonstrated moderate agreement with expert assessments, offering a potential solution to variability and limited access to expert musculoskeletal radiology. These innovations may support earlier diagnosis and reduce misclassification. Innovative models of care, including patient-initiated telemedicine visits, reduced in-person visit frequency without compromising clinical outcomes in patients with stable axSpA. Updated Canadian treatment guidelines introduced more robust data on Janus kinase (JAK) inhibitors and offered stronger support for tapering biologics in patients with sustained low disease activity or remission, while advising against abrupt discontinuation. This clinical and imaging year in review covers challenges and innovations in axSpA, emphasizing the need for early access to care and the development of tools to support prompt diagnosis and sustained continuity of care.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"29"},"PeriodicalIF":4.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging Artificial Intelligence Innovations in Rheumatoid Arthritis and Challenges to Clinical Adoption. 类风湿性关节炎的新兴人工智能创新和临床应用的挑战。

IF 4.9 2区医学

Current Rheumatology Reports Pub Date : 2025-06-28 DOI: 10.1007/s11926-025-01193-w

Vinit J Gilvaz, Aishwarya Sudheer, Anthony M Reginato

{"title":"Emerging Artificial Intelligence Innovations in Rheumatoid Arthritis and Challenges to Clinical Adoption.","authors":"Vinit J Gilvaz, Aishwarya Sudheer, Anthony M Reginato","doi":"10.1007/s11926-025-01193-w","DOIUrl":"10.1007/s11926-025-01193-w","url":null,"abstract":"Purpose of review: This review was written to inform practicing clinical rheumatologists about recent advances in artificial intelligence (AI) based research in rheumatoid arthritis (RA), using accessible and practical language. We highlight developments from 2023 to early 2025 across diagnostic imaging, treatment prediction, drug discovery, and patient-facing tools. Given the increasing clinical interest in AI and its potential to augment care delivery, this article aims to bridge the gap between technical innovation and real-world rheumatology practice.Recent findings: Several AI models have demonstrated high accuracy in early RA detection using imaging modalities such as thermal imaging and nuclear scans. Predictive models for treatment response have leveraged routinely collected electronic health record (EHR) data, moving closer to practical application in clinical workflows. Patient-facing tools like mobile symptom checkers and large language models (LLMs) such as ChatGPT show promise in enhancing education and engagement, although accuracy and safety remain variable. AI has also shown utility in identifying novel biomarkers and accelerating drug discovery. Despite these advances, as of early 2025, no AI-based tools have received FDA approval for use in rheumatology, in contrast to other specialties. Artificial intelligence holds tremendous promise to enhance clinical care in RA-from early diagnosis to personalized therapy. However, clinical adoption remains limited due to regulatory, technical, and implementation challenges. A streamlined regulatory framework and closer collaboration between clinicians, researchers, and industry partners are urgently needed. With thoughtful integration, AI can serve as a valuable adjunct in addressing clinical complexity and workforce shortages in rheumatology.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"28"},"PeriodicalIF":4.9,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advances in the Immunopathology of Axial Spondyloarthritis: with and without HLA-B27. 轴型脊柱性关节炎的免疫病理研究进展：伴和不伴HLA-B27。

IF 4.9 2区医学

Current Rheumatology Reports Pub Date : 2025-06-21 DOI: 10.1007/s11926-025-01194-9

Brian Wu, Amy Tang, Akihiro Nakamura

{"title":"Recent Advances in the Immunopathology of Axial Spondyloarthritis: with and without HLA-B27.","authors":"Brian Wu, Amy Tang, Akihiro Nakamura","doi":"10.1007/s11926-025-01194-9","DOIUrl":"10.1007/s11926-025-01194-9","url":null,"abstract":"Purpose of review: Axial spondyloarthritis (axSpA) is a chronic multi-organ rheumatic disease affecting various tissues, and recent key advancements have provided significant insight into understanding its immunopathology.Recent findings: Expanded CD8⁺ T cell subsets bearing unique T cell receptor (TCR) motifs (TRAV21/TRBV9) in HLA-B27-positive axSpA patients or those with acute anterior uveitis were recently identified. These T cells can bind to self- and bacterial-derived peptides, supporting the \"arthritogenic peptide\" hypothesis. Monoclonal antibody-mediated elimination of these expanded T cells has shown potential as a novel treatment for axSpA in a phase II clinical trial, offering a groundbreaking therapeutic approach. In addition to T cells, neutrophils have emerged as important mediators of both inflammation and new bone formation in axSpA, potentially contributing to HLA-B27-independent immune pathomechanisms. Key neutrophil-derived molecules-such as macrophage migration inhibitory factor, hypoxia-inducible factor 1-alpha, caspase recruitment domain-containing protein 9, and neutrophil extracellular traps (NETs)-have been shown in preclinical models to promote Th17-mediated inflammation and reduce regulatory T cell numbers. These mechanisms may be relevant to axSpA pathogenesis and represent potential new therapeutic targets. In recent years, significant progress has been made in understanding the immunopathology of axSpA through both HLA-B27-dependent and -independent mechanisms. However, key questions remain. The pathogenic HLA-B27:05-bound peptides driving CD8⁺ T cell expansion remain unidentified. Moreover, due to the diversity of TCR motifs that recognize self- and microbial peptides, therapies targeting a single TCR (e.g., TRBV9) may have limited efficacy. Further research is needed to clarify axSpA pathogenesis across both pathways.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"27"},"PeriodicalIF":4.9,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Family Planning and Rheumatoid Arthritis. 计划生育与类风湿性关节炎。

IF 4.9 2区医学

Current Rheumatology Reports Pub Date : 2025-05-29 DOI: 10.1007/s11926-025-01191-y

Catherine Sims, Mehret Birru Talabi

{"title":"Family Planning and Rheumatoid Arthritis.","authors":"Catherine Sims, Mehret Birru Talabi","doi":"10.1007/s11926-025-01191-y","DOIUrl":"10.1007/s11926-025-01191-y","url":null,"abstract":"Purpose of review: Patients with rheumatoid arthritis (RA) need tailored guidance when it comes to family planning decisions, including contraception, pregnancy, and breastfeeding. To achieve the best reproductive health outcomes, a coordinated, multidisciplinary approach is essential. This article aims to support healthcare providers in addressing key reproductive health concerns for both male and female patients, such as timing conception, infertility, and the management of RA medications during pregnancy and lactation.Recent findings: Some women with RA may experience subfertility, however assisted reproductive technology is a safe option. RA disease activity may change for some women during pregnancy, but this is influenced by disease activity going into pregnancy and medication use in pregnancy. Pregnancy complications are more common among women with RA compared to the general population, which may be explained, in part, by disease activity, extra-articular manifestations of RA, and/or use of certain medications. Neonates exposed to biologic medications in utero can receive all recommended vaccinations. Contraception, including emergency contraception, is safe for women with RA. Preliminary data suggests pregnancy termination is safe in women with RA and does not increase the risk for disease flare. RA is a chronic inflammatory disease that can impact both women and men during their reproductive years. Rheumatologists have an essential role in patient's reproductive health and family planning. This article highlights key considerations and offers strategies to assist providers in understanding and supporting their patients' reproductive goals.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"26"},"PeriodicalIF":4.9,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breaking Barriers: Essential Reforms for a Competitive and Affordable Biosimilars Market. 打破壁垒：竞争和负担得起的生物仿制药市场的基本改革。

IF 4.9 2区医学

Current Rheumatology Reports Pub Date : 2025-05-28 DOI: 10.1007/s11926-025-01192-x

Eric T Roberts, Jinoos Yazdany

{"title":"Breaking Barriers: Essential Reforms for a Competitive and Affordable Biosimilars Market.","authors":"Eric T Roberts, Jinoos Yazdany","doi":"10.1007/s11926-025-01192-x","DOIUrl":"10.1007/s11926-025-01192-x","url":null,"abstract":"Purpose of review: This update examines the current policy landscape for biosimilars, particularly those approved for treating rheumatoid arthritis. We review recent literature and recommend policies to align the biosimilars market with the goals of the Biologic Price Competition and Innovation Act (BPCIA). We examine updated evidence on biosimilar safety and effectiveness, recent FDA guidance on interchangeability, and challenges posed by anti-competitive behaviors and government regulations. Additionally, we analyze financial incentives and market dynamics affecting biosimilar adoption and competition.Recent findings: Building on the extensive body of RCT data demonstrating the safety and effectiveness of biosimilars, real-world evidence from North America and Europe now confirms these findings, including in patients who switched therapies. Increased biosimilar prescribing will depend on disseminating safety data and strategies to enhance patient-physician communication. The FDA updated its interchangeability guidance to no longer require large clinical studies, citing updated understanding of safety data; this may facilitate more direct price-based competition. Congress and the Federal Trade Commission need to address anticompetitive behaviors including patent law loopholes, the role of PBMs in inflating drug prices, vertical integration of healthcare conglomerates, and changes to funding for government agencies charged with reviewing biosimilar drugs. Medicare reimbursement rates and the 340B program still unfairly incentivize use of bio-originator products. There are many barriers to achieving the goals of the BPCIA. With necessary changes, the U.S. can realize the goal of a competitive and sustainable biosimilar market that gradually reduces total drug expenditures and out-of-pocket costs over time without stifling innovation.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"27 1","pages":"25"},"PeriodicalIF":4.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0